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Introduction {#jgh312090-sec-0005}
============

Celiac disease (CD) is a chronic inflammatory condition of the small intestine, initiated by the ingestion of dietary gluten peptides (contained in wheat, rye, and barley) in genetically susceptible individuals.[1](#jgh312090-bib-0001){ref-type="ref"} The presence of HLA‐DQ2 and/or ‐DQ8 haplotypes, identified in the HLA class II histocompatibility system expressed on the surface of antigen‐presenting cells (APC), mainly macrophages, dendritic cells, and B cells, is considered as a necessary risk factor for the development of CD. Risk of CD is excluded if both genotypes are absent, with nearly 95% confidence.[2](#jgh312090-bib-0002){ref-type="ref"}

In a recent systematic review and meta‐analysis, we observed that 1.37% of the global population is seropositive for CD, and 0.68% of the global population is estimated to have biopsy‐confirmed CD.[3](#jgh312090-bib-0003){ref-type="ref"} Furthermore, various landmark studies have reported a worldwide increase in the prevalence of CD in the past few decades.[3](#jgh312090-bib-0003){ref-type="ref"}, [4](#jgh312090-bib-0004){ref-type="ref"}, [5](#jgh312090-bib-0005){ref-type="ref"}, [6](#jgh312090-bib-0006){ref-type="ref"}, [7](#jgh312090-bib-0007){ref-type="ref"} While CD was thought to be uncommon in India, in a pan‐India population‐based study involving more than 23 331 subjects, we observed that 0.68% of Indians have either potential CD or CD.[8](#jgh312090-bib-0008){ref-type="ref"} While a large number of subjects is expected to have CD, the majority still remains undiagnosed.[5](#jgh312090-bib-0005){ref-type="ref"}

The HLA‐DQ2 heterodimer associated with the susceptibility to CD is formed by an alpha chain encoded by the HLA‐DQA1\*05 allele and a beta chain encoded by the HLA‐DQB1\*02 allele (now defined as HLA‐DQ 2.5).[9](#jgh312090-bib-0009){ref-type="ref"} These two HLA alleles (in either *cis* or *trans* position) are present in at least 90% of patients with CD.[10](#jgh312090-bib-0010){ref-type="ref"}, [11](#jgh312090-bib-0011){ref-type="ref"} The HLA‐DQ8 heterodimer is found in 5% of CD patients and is formed by an alpha chain and beta chain encoded by HLA‐DQA1\*03 and HLA‐DQB1\*03:02, respectively.[10](#jgh312090-bib-0010){ref-type="ref"}, [12](#jgh312090-bib-0012){ref-type="ref"} However, HLA‐DQ2 or HLA‐DQ8 are expressed in almost 30--55% of the general population.[13](#jgh312090-bib-0013){ref-type="ref"}, [14](#jgh312090-bib-0014){ref-type="ref"} HLA‐DQ2/‐DQ8 typing is currently considered as an additional diagnostic test for CD, particularly useful when taking clinical decisions where there are discrepancies between celiac‐specific serological tests and intestinal mucosal biopsies and for the screening of "at‐risk" individuals, such as first‐degree relatives (FDRs) of patients with CD; patients with type 1 diabetes; and patients with chromosomal diseases such as William\'s syndrome, Turner syndrome, and Down\'s syndrome.[15](#jgh312090-bib-0015){ref-type="ref"}, [16](#jgh312090-bib-0016){ref-type="ref"}, [17](#jgh312090-bib-0017){ref-type="ref"}, [18](#jgh312090-bib-0018){ref-type="ref"}, [19](#jgh312090-bib-0019){ref-type="ref"}, [20](#jgh312090-bib-0020){ref-type="ref"} Due to its high negative predictive value, it is helpful in excluding the subjects requiring further investigations and may find application in both mass screening or case finding strategies. A combination of different serological tests (e.g. IgA anti‐transglutaminase, anti‐endomysial ab) with HLA DQ‐2/‐DQ8 genotyping can strengthen the serological test result and could minimize the burden of unnecessary duodenal biopsies.[21](#jgh312090-bib-0021){ref-type="ref"} In the recent European pediatric guidelines (European Society for Pediatric Gastroenterology Hepatology and Nutrition \[ESPGHAN\]) for the diagnosis of CD, HLA typing is indicated as an adjunctive and an appropriate test to avoid the mucosal biopsies in patients demonstrating symptoms and a high titer of celiac autoantibodies (i.e. IgA anti‐transglutaminase).[22](#jgh312090-bib-0022){ref-type="ref"}

There are several HLA‐DQ typing approaches currently available, such as polymerase chain reaction‐sequence‐specific primers (PCR‐SSP), PCR‐sequence‐specific oligonucleotide probes (PCR‐SSOP), real‐time PCR (RT‐PCR), and microarray.[2](#jgh312090-bib-0002){ref-type="ref"} Commercially available kits used to perform these tests are expensive and time consuming, and their methodologies are complex, requiring a well‐trained technician to perform the test. Duration of analysis, costs, and availability of these tests limit their widespread use in the clinical practice. There is an unmet need for an accurate, quick, easy, and affordable method to perform HLA‐DQ typing.

To make HLA‐DQ typing easy and inexpensive, we proposed a new‐fangled, reliable, and unambiguous sequence‐specific primer‐based rapid, single PCR HLA‐DQ typing method, "Celiac Gene Screen," developed by BioDiagene S.R.L (Palermo, Italy). This quick HLA‐DQ typing test isolates DNA in approximately 1 min and runs total PCR (amplification of HLA‐DQ alleles) in 90 min. The Celiac Gene Screen HLA‐DQ typing kit provides information on the presence/absence of HLA‐DQ2 and/or ‐DQ8 alleles (yes/no), without identification of all critical HLA alleles necessary to identify the CD risk heterodimers.

The aim of this study was to validate the accuracy of the "Celiac Gene Screen" through a comparison of this new test with the conventional HLA‐DQ alleles typing test (SSOP‐PCR method).

Methods {#jgh312090-sec-0006}
=======

During June 2017, the rapid HLA‐DQ typing method, "Celiac Gene Screen," was applied to the stored EDTA blood samples collected from the biorepository of the Celiac Clinic of the Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India. This study was approved by the Ethics Committee of the institution.

Selection of blood samples {#jgh312090-sec-0007}
--------------------------

In the present study, we included a total of 400 blood samples that had been collected in EDTA blood collection vials on earlier occasions and were stored in the biorepository of our institution. These samples had been collected during a community prevalence study that was conducted earlier and also from patients with CD being followed up at our center. Written and informed consent was requested from all the participants during the respective studies. To determine the diagnostic performance of the Celiac Gene Screen kit, we tested 100 blood samples in which HLA genotyping had already been characterized by the conventional SSOP‐PCR with the Luminex‐based One Lambda (LAB Type SSO Class II DQA1/DQB1 typing kit, CA, USA). In the remaining 300 EDTA blood samples where HLA‐DQ status had not been assessed previously, 141 samples were collected from patients with CD (having IgA anti‐tTG ab positivity and villous abnormality of modified Marsh grade 2 or more), 56 samples from FDRs of patients with CD and 103 IgA anti‐tTG negative samples (controls).

The procedure of the Celiac Gene Screen kit {#jgh312090-sec-0008}
-------------------------------------------

The Celiac Gene Screen kit involves three major steps, including preliminary lysis of EDTA blood sample, DNA amplification (one reaction/test), and fluorescence detection using a BioRun Reader. The total procedure time of this test to obtain the final result is less than 2 h. During the HLA‐DQ typing procedure, manufacturer\'s guidelines were strictly followed. Major steps of the procedure are described below.

### Step 1: lysis of blood samples collected in EDTA tubes {#jgh312090-sec-0009}

Tubes containing EDTA blood samples were allowed to thaw at room temperature and vortexed gently. For each blood sample, 200 μl of extraction buffer (provided with the Celiac Gene Screen kit) was poured in a 1.5‐ml Eppendorf tube. Ten microliter of EDTA blood was mixed with the extraction buffer and incubated at room temperature for 1 min. This step facilitated quick DNA isolation. Of this lysate, 2 μl was used further for the DNA amplification.

### Step 2: amplification of HLA‐DQ alleles {#jgh312090-sec-0010}

In 0.2‐ml PCR tubes provided with the Celiac Gene Screen kit, containing dried primers/probes for a housekeeping gene (internal control) and the target alleles, 18 μl of ready‐to‐use Taq mix (provided with the kit) and 2 μl of isolated DNA were mixed by pipetting. PCR tubes were vortexed for about 15 s and were then placed into a thermocycler. After 90 min of PCR run, tubes were ready for use in the analysis.

### Step 3: detection of HLA‐DQ alleles {#jgh312090-sec-0011}

PCR tubes were placed in the BioRun Reader. In‐built software analyzed all the data at once and gave the interpretation in 10--20 s. The Celiac Gene Screen identifies the alleles DQB1\*02 codifying for the beta chain of the DQ2 antigen and the DQB1\*03:02 alleles codifying for the DQ8 beta chain. In each BioDiagene PCR tube, two fluorescence probes corresponding to primers were also coated, one that recognized the housekeeping gene and the second one that was perfectly complementary to that of the target DNA. The tubes were excited with two well‐defined wavelengths. The increase in the reported fluorescent signal was directly proportional to the number of amplicons generated. Therefore, depending on the fluorescence value in the tube, the BioRun Reader reported the presence or absence of CD‐associated alleles in the sample.

Statistical analysis {#jgh312090-sec-0012}
--------------------

Quantitative variables were summarized as the mean ± SD; 95% confidence interval (CI) was calculated using the Software Program Stata System (SPSS) IBM version 25, Chicago, USA.

Results {#jgh312090-sec-0013}
=======

Concordance of Celiac Gene Screen Kit with conventional HLA‐DQ2 and ‐DQ8 typing method {#jgh312090-sec-0014}
--------------------------------------------------------------------------------------

Of 100 blood samples (mean age ± SD: 25.3 ± 11.1 years; 40 males) with a known status of HLA‐DQ2 and ‐DQ8, 79 samples (mean age ± SD: 24.5 ± 10.7 years, 31 males) were HLA‐DQ2 and/or ‐DQ8 positive, and 21 samples (mean age ± SD: 28.4 ± 12.5 years; 9 males) were HLA‐DQ2 and ‐DQ8 negative by the conventional SSOP HLA typing method. These 100 samples were regenotyped using the Celiac Gene Screen kit, and all of the 79 HLA‐DQ2 and/or ‐DQ8 positive samples were positive, and all the 21 HLA‐DQ2 and ‐DQ8 negative samples were typed negative by the Celiac Gene Screen Kit as well. This shows an excellent concordance (100%) rate between HLA testing using the SSOP HLA typing method and the Celiac Gene Screen method (Fig. [1](#jgh312090-fig-0001){ref-type="fig"}).

![HLA‐DQ2/‐DQ8 status in the samples selected in the study. CD, celiac disease; EDTA, ethylenediaminetetraacetic acid; HLA, human leukocyte antigen; PCR, polymerase chain reaction; SSOP, sequence‐specific oligonucleotide probes.](JGH3-2-311-g001){#jgh312090-fig-0001}

HLA DQ status in CD samples {#jgh312090-sec-0015}
---------------------------

Of 300 samples with unknown HLA‐DQ status (mean age ± SD: 30 ± 14.7 years; 145 males), 141 blood samples (mean age ± SD: 30 ± 14 years; 68 males) were from patients with CD. Of these, 118 (84%, 95% CI: 78--90) samples (mean age ± SD: 26.2 ± 13.5 years; 57 males) showed HLA‐DQ2 and/or ‐DQ8 positivity, and 23 (16%, 95% CI: 10--22) samples (mean age ± SD: 30.7 ± 14.1 years; 11 males) were HLA‐DQ2 and ‐DQ8 negative (Fig. [1](#jgh312090-fig-0001){ref-type="fig"}).

HLA DQ status in FDRs of patients with CD {#jgh312090-sec-0016}
-----------------------------------------

Of 56 samples (mean age ± SD: 27.4 ± 13.9 years; 33 males) from FDRs, 48 (86%, 95% CI: 85--87%) samples (mean age ± SD: 28.1 ± 14.4 years; 32 males) tested positive for HLA‐DQ2 and/or ‐DQ8. On the other hand, eight (14%, 95% CI: 5--23) samples (mean age ± SD: 23.2 ± 10.8 years; 1 male) were HLA‐DQ2 and/or DQ8 negative (Fig. [1](#jgh312090-fig-0001){ref-type="fig"}).

HLA‐DQ status in control samples {#jgh312090-sec-0017}
--------------------------------

In 103 samples (mean age ± SD: 38.4 ± 13.5 years; 44 males) from control subjects, 52 (50%, 95% CI: 40--60) samples (mean age 36.7 ± 13.2 years; 18 males) were HLA‐DQ2 and/or ‐DQ8 positive, whereas the remaining 51 (50%, 95% CI: 40--60) samples (mean age ± SD: 40.3 ± 13.9 years; 26 males) were reported to be HLA‐DQ2 and ‐DQ8 negative (Fig. [1](#jgh312090-fig-0001){ref-type="fig"}).

Discussion {#jgh312090-sec-0018}
==========

HLA‐DQ genes (HLA ‐DQ2/‐DQ8) play a primary role in the development of CD. Clinically, HLA‐DQ genotyping does not provide a final diagnosis of the CD but indicates the necessary predisposition required for the development of CD.[23](#jgh312090-bib-0023){ref-type="ref"}, [24](#jgh312090-bib-0024){ref-type="ref"} Due to its high negative predictive value, the absence of HLA‐DQ predisposing alleles makes the diagnosis of CD unlikely. Different combinations of HLA‐DQ CD predisposing alleles also determine the level of risk of CD development. For instance, individuals presenting a double dose of the HLA‐DQ B1\*02 variant remain at high risk of developing CD in comparison to those expressing a single dose of the DQB1\*02 allele.[25](#jgh312090-bib-0025){ref-type="ref"}, [26](#jgh312090-bib-0026){ref-type="ref"} At‐risk subjects, such as FDRs of patients with CD; patients with other autoimmune diseases (type 1 diabetes); and individuals with Williams, Turner, and Down\'s syndrome showing HLA‐DQ2 and ‐DQ8 negativity, particularly in Western countries, remain out of risk of developing CD on a lifelong basis.[16](#jgh312090-bib-0016){ref-type="ref"}, [17](#jgh312090-bib-0017){ref-type="ref"}, [18](#jgh312090-bib-0018){ref-type="ref"}, [19](#jgh312090-bib-0019){ref-type="ref"}, [20](#jgh312090-bib-0020){ref-type="ref"} A single HLA determination in such subjects may set them free from future surveillance and unnecessary follow‐up in the clinic (repetitive serology, duodenal endoscopy/biopsy).[27](#jgh312090-bib-0027){ref-type="ref"}

Furthermore, a duodenal biopsy may be avoided in some subjects if one demonstrates that the patient has a genetic susceptibility to CD by showing the presence of HLA‐DQ2/‐DQ8 haplotype if they have a positive antiendomysial antibody (EMA) and high titer of antitissue transglutaminase antibody (IgA anti‐tTG ab). However, the latest ESPGHAN guideline specifically recommends avoiding histological assessment in children and adolescents with signs or symptoms suggestive of CD with high anti‐tTG ab titers with levels \>10 times the upper limits of normal (ULN), supported by a positive EMA test, also with positive HLA‐DQ2 and/or HLA‐DQ8 alleles.[22](#jgh312090-bib-0022){ref-type="ref"} The ESPGHAN guideline also recommends HLA‐DQ‐2.5/‐DQ8 typing in all type 1 diabetes mellitus patients for screening of CD and encourages the assessment of HLA‐DQ2.5/‐DQ8 genotyping as the first screening tool in asymptomatic individuals with a family risk of CD.[22](#jgh312090-bib-0022){ref-type="ref"}

Conventional HLA‐DQ typing is an expensive method. Due to its high cost, HLA‐DQ typing is not performed in many studies, and a considerable number of at‐risk individuals do not undergo this test.[28](#jgh312090-bib-0028){ref-type="ref"} At our center (AIIMS) in New Delhi, HLA‐DQ2/‐DQ8 typing (high resolution) costs approximately 3000 Indian rupees (INR)/test (approximately US Dollar \$46/test), while private laboratories in New Delhi offer this test at about 9000 INR/test (approximately USD138/test). In Italy, the cost of HLA genotyping varies from €46 to €180/test. In other parts of Europe, HLA‐DQ typing costs €167--€326/test, and within the United States, in the nonprofit private medical center, HLA‐DQ typing costs approximately USD 350/test.[29](#jgh312090-bib-0029){ref-type="ref"}, [30](#jgh312090-bib-0030){ref-type="ref"} The cost of HLA‐DQ genotyping in our study was much lower (per test price by manufacturer, about €15, excluding all other laboratory costs). However, we wish to emphasize that the Celiac Gene Screen kit is a low‐resolution test most suitable for CD‐associated screening studies. It covers the set of critical HLA alleles necessary to identify the CD risk heterodimers (DQB1\*02 and DQB1\*03:02 alleles). An affordable price for HLA‐DQ typing may increase the use of this test in developing countries, especially for CD screening studies, and may help physicians resolve many clinical dilemmas related to CD diagnosis.

In the present study, we compared the efficacy of a novel rapid HLA‐DQ2 and/or ‐DQ8 typing kit ("Celiac Gene Screen Kit") with that of the conventional SSOP HLA‐DQ typing method. We observed an excellent (100%) concordance rate in the reporting of two methods. We also determined the HLA‐DQ status in blood samples collected from different groups (CD, FDRs of CD patients and controls) where HLA‐DQ status was not known previously. In the present study, we observed that 84% of patients with CD were HLA‐DQ2/‐DQ8 positive compared with approximately 90--95% Caucasian CD patients in Europe and the United States.[10](#jgh312090-bib-0010){ref-type="ref"}, [11](#jgh312090-bib-0011){ref-type="ref"} The results of this study match the observations in our previous population‐based study, where we observed that about 76% of patients from the northern part of India detected to have CD were HLA‐DQ2/‐DQ8 positive.[8](#jgh312090-bib-0008){ref-type="ref"} There may be another HLA genotype in the rest of North Indian patients with CD. A high throughput HLA DQ allele characterization may identify the risk alleles for these 23 (16%) negative HLA but confirmed CD samples. However, these 23 CD patients who were typed negative for HLA‐DQ alleles had a high titer of anti‐tTG ab and had villous abnormality of Modified Marsh grade between 3a and 3c (Appendix [S1](#jgh312090-supitem-0001){ref-type="supplementary-material"}, Supporting Information). One pediatric patient was exempted from duodenal endoscopy biopsy test as he or she had a significantly higher level of anti‐tTG ab. In FDRs of CD patients and control subjects, the percentage of HLA‐DQ2 and/or ‐DQ8 positivity was in line with other well‐designed CD prevalence studies.[31](#jgh312090-bib-0031){ref-type="ref"}, [32](#jgh312090-bib-0032){ref-type="ref"}, [33](#jgh312090-bib-0033){ref-type="ref"}

Small sample size was a limitation of this study. A higher number of samples could have provided a more robust result. This test does not provide homo‐ or heterozygous status; instead, it only reveals the presence or absence of CD‐associated alleles (HLA‐DQ2/‐DQ8). Nevertheless, this method can be useful in screening both individuals at risk of CD and the general population. The advantage of this test is to provide HLA‐DQ2 and/or‐DQ8 status quickly. Setting up this machinery in standard‐level laboratories is feasible and quite easy. Unlike the conventional HLA‐DQ typing method, this method does not involve complex steps and is not restricted to deeply trained and experienced laboratory personnel.

To make HLA‐DQ typing easy, more than a few sincere efforts have been made to deliver a simpler but reliable HLA‐DQ typing test. In recent times, several easy‐to‐perform commercial HLA‐DQ typing kits have been introduced, claiming to be able to characterize celiac‐associated genes (HLA‐DQ genes) specifically, unambiguously, and exactly by using conventional HLA‐DQ typing methods with overlapping sensitivity to the conventional ones. While these tests are easier than the conventional method, they require critical steps to be performed as DNA isolation has to be performed either manually (that takes several hours) or using a rapid kit‐based method for DNA amplification (PCR run), and the amplicons have to be run on an agarose gel to read for interpretation of HLA‐DQ status.[13](#jgh312090-bib-0013){ref-type="ref"}, [24](#jgh312090-bib-0024){ref-type="ref"}, [34](#jgh312090-bib-0034){ref-type="ref"}, [35](#jgh312090-bib-0035){ref-type="ref"} The celiac gene screen HLA‐DQ typing test makes every step easier, from DNA isolation (few minutes) to PCR run (90 min), and results in interpretation (within minutes). Furthermore, to the best of our current knowledge, in comparison to conventional and other commercially available HLA‐DQ typing methods we have explored, the Celiac Gene Screen HLA‐DQ typing method costs less and is probably the easiest, quickest, and most economical and reliable method to identify celiac‐associated alleles.[24](#jgh312090-bib-0024){ref-type="ref"}, [29](#jgh312090-bib-0029){ref-type="ref"}, [30](#jgh312090-bib-0030){ref-type="ref"}

In conclusion, the Celiac Gene Screen method showed excellent concordance with the conventional HLA‐DQ typing test (SSOP‐PCR). This is a rapid, easy‐to‐conduct, and relatively less expensive method for the specific and unambiguous detection of CD‐associated HLA alleles. The Celiac Gene Screen kit can be an effective tool for CD‐associated HLA screening, which could be particularly useful whenever problems of budget limitations hamper the possibility of applying this important diagnostic method.

Supporting information
======================

###### 

**Appendix S1** Clinical features of celiac disease patients, typed HLA‐DQ2/‐DQ8 negative using the Celiac Gene Screen method.

###### 

Click here for additional data file.

We acknowledge the support of BioDiagene S.R.L (Palermo, Italy) in providing the Celiac Gene Screen kit. We thank Emanuela Maria Mariani (Department of Pediatrics, Università Politecnica delle Marche, Ancona Italy) for the execution of administrative work. We appreciate and thank the Università Politecnica delle Marche (Ancona, Italy) for approving funds for travel. We acknowledge and recognize the support and the help of Anu Verma (Ancona, Italy) in assisting with the study of data entry. We appreciate the contribution of students and staff of the Department of Gastroenterology and Human Nutrition, AIIMS, New Delhi, India, for their support.
